Event Title
The New Expansion of the Growth Hormone, Humatrope - Are you Short Enough?
Location
CSU 253
Start Date
13-4-2004 10:30 AM
End Date
13-4-2004 12:00 PM
Student's Major
Communication Studies
Student's College
Arts and Humanities
Mentor's Name
Leah White
Mentor's Department
Communication Studies
Mentor's College
Arts and Humanities
Description
For the past two decades, Humatrope, a growth hormone used on both adults and children, was strongly restricted for the use on children. Children had to be suffering from a diagnosed growth disease in order to receive treatment or insurance coverage. However, Newsweek of September 22, 2003 reported the drug manufacture; Eli Lilly & Company received the FDA's approval this summer to expand the application of Humatrope, to now include children with "idiopathic short stature," meaning shortness without a medical explanation. Children with unexplained, undiagnosable shortness are now eligible for Humatrope treatment. Humatrope merits our examination , not because the drug itself is revolutionary, but Lilly's new application is: on seemingly healthy children who have failed to grow, but the cause is unknown. This expansion is relevant to the public because it is about access to medication and a patient's right to decide what is best for their own health.
The New Expansion of the Growth Hormone, Humatrope - Are you Short Enough?
CSU 253
For the past two decades, Humatrope, a growth hormone used on both adults and children, was strongly restricted for the use on children. Children had to be suffering from a diagnosed growth disease in order to receive treatment or insurance coverage. However, Newsweek of September 22, 2003 reported the drug manufacture; Eli Lilly & Company received the FDA's approval this summer to expand the application of Humatrope, to now include children with "idiopathic short stature," meaning shortness without a medical explanation. Children with unexplained, undiagnosable shortness are now eligible for Humatrope treatment. Humatrope merits our examination , not because the drug itself is revolutionary, but Lilly's new application is: on seemingly healthy children who have failed to grow, but the cause is unknown. This expansion is relevant to the public because it is about access to medication and a patient's right to decide what is best for their own health.
